4:11 PM
 | 
Jun 07, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Exact HCC assay significantly better than SOC

Exact Sciences Corp. (NASDAQ:EXAS) reported data showing that its hepatocellular carcinoma blood test had greater sensitivity and specificity in identifying HCC, especially early stage cancer, vs. the standard of care alpha fetoprotein (AFP) test.

The test is the most advanced in Exact's pipeline behind its marketed Cologuard colorectal cancer screening test.

In the Phase II case-control study, Exact's test was significantly better at discriminating HCC from cirrhotic controls vs. the AFP test, with an area under the receiver operating characteristics curve (AUC) of...

Read the full 394 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >